16 Years Later: Boston Scientific's Strategic Return to the Neurovascular Market
Written by Kfir Kedem
Every year, millions of people suffer ischemic strokes, a condition where a blood clot blocks blood flow to the brain. Neurovascular medicine is the field dedicated to treating these conditions, relying heavily on specialized medical devices to physically remove clots and restore circulation. The companies that develop these devices operate in one of the fastest growing and most consequential segments of the medical technology industry.
Contextual evolution from 2010 to 2026 Boston Scientific Acquires Penumbra for $14.5B
Neurovascular Deal Analysis and Market Insight Boston Scientific is acquiring Penumbra for $14.5B. But why now? This acquisition represents one of the largest neurovascular medical device deals in recent years and highlights strategic growth in thrombectomy systems.
Penumbra develops and manufactures vascular and neurovascular medical devices with a special focus on thrombectomy systems. Basically, equipment used in medical procedures to remove blood clots under image guidance. These procedures treat ischemic stroke and other neurovascular conditions, making Penumbra a leader in minimally invasive stroke intervention technologies.
Boston Scientific is a leading medical technology company with a large portfolio that has grown over the past 45 years and includes the following technologies:
· Cardiac Rhythm Management
· Electrophysiology
· Endoscopy
· Interventional Cardiology Therapies
· Neuromodulation
· Peripheral Interventions
· Urology
· WATCHMAN Implant
The company has had a strategy of growth through acquisition of innovative medical device companies and exited the neurovascular space in 2010 when they sold this portion of their business to Stryker for $1.5B. The road to this sale was led by bad timing and a challenging market environment. In 2006, Guidant was being pursued for acquisition by Johnson & Johnson (J&J) when one of their defibrillators failed in a patient’s heart, leading to a recall of all such devices. Boston Scientific entered the bidding war and ultimately acquired Guidant for $27B, using approximately $17B of leverage.
Boston Scientific incurred significant litigation, settlement, and compliance costs associated with inherited Guidant product issues, as well as $2.4B in lawsuits and patent infringement liabilities. Given the high leverage and costs, Boston Scientific was constrained in investing in innovation and market expansion for neurovascular products.
In 2010, Boston Scientific initiated a portfolio simplification and sold the neurovascular business to Stryker at approximately 3x annual revenue.
The global neurovascular technology market was roughly $1.5B in 2010. Mechanical thrombectomy was still emerging and not widely adopted as standard care, with low margins due to clinical trial requirements, physician training, specialized sales forces, and ongoing device innovation. Specialized competitors like Stryker were favored for this market.
By 2026, the global neurovascular market is $4B and forecasted to double by the early 2030s. Mechanical thrombectomy is now guideline-supported standard care for large-vessel-occlusion stroke patients in the US and Europe. With market growth and improved financial health, Boston Scientific is strategically positioned to expand into neurovascular technologies in 2026.
Projections
Using the financial statements of Penumbra as taken from their 2025 and 2024 SEC filings, the future cash flows can be projected and discounted, leading to a valuation.
The historical income statements of the last four years are below:
Line Item * 1000 | 2025 | 2024 | 2023 | 2022 |
Revenue | 1,327,190.00 | 1,194,615.00 | 1,058,522.00 | 847,133.00 |
Cost of revenue | 447,404.00 | 439,620.00 | 375,879.00 | 311,926.00 |
Gross profit | 879,786.00 | 754,995.00 | 682,643.00 | 535,207.00 |
Research and development | 90,590.00 | 94,783.00 | 84,423.00 | 79,407.00 |
Sales, general and administrative | 626,840.00 | 573,988.00 | 506,454.00 | 449,718.00 |
Acquired in-process R&D |
| - | 18,215.00 | - |
Impairment charge | - | 76,945.00 | - | - |
Total operating expenses | 717,430.00 | 745,716.00 | 609,092.00 | 529,125.00 |
Income from operations | 162,356.00 | 9,279.00 | 73,551.00 | 6,082.00 |
Interest and other income, net | 15,980.00 | 11,590.00 | 6,099.00 | (2,190.00) |
Income before income taxes | 178,336.00 | 20,869.00 | 79,650.00 | 3,892.00 |
Provision for income taxes | 9,350.00 | 6,857.00 | (11,304.00) | 5,894.00 |
Net income (loss) | 168,986.00 | 14,012.00 | 90,954.00 | (2,002.00) |
The 2025 figures have been multiplied by two to represent a full period as only half period values were available. The average and growth values for key line items were calculated. Furthermore, depreciation & amortization values, CapEx expenditures, and changes in net working capital were taken from the balance sheets and cash flow statements that are also available in the company’s SEC filings. Additionally, the WACC and growth rate of this market were taken directly from Boston Scientific’s website. As such, we are able to project future line items and discount free cash flows in order to get a valuation of Penumbra:
Line Item | 2025 | 2026 | 2027 | 2028 | 2029 | Past 2029 |
Revenue | 1,327,190.00 | 1,541,441.10 | 1,790,279.21 | 2,079,287.78 | 2,414,951.62 | |
Gross Profit | 879,786.00 | 1,037,795.19 | 1,223,892.38 | 1,443,028.41 | 1,701,020.60 | |
Operating Expense | 717,430.00 | 895,892.72 | 1,022,615.79 | 1,166,905.95 | 1,331,132.54 | |
Operating Income | 162,356.00 | 141,902.47 | 201,276.58 | 276,122.46 | 369,888.05 | |
Operating Margin | 12.23% | 9.21% | 11.24% | 13.28% | 15.32% | |
Net Income | 168,986.00 | 125,257.31 | 177,666.84 | 243,733.29 | 326,500.18 | |
Depreciation & Amortization | 21,044.00 | 17,836.76 | 13,045.60 | 6,242.72 | - | |
CapEx | (20,149.13) | (23,401.85) | (27,179.66) | (31,567.33) | (36,663.31) | |
ΔNWC | 26,543.80 | 30,828.82 | 35,805.58 | 41,585.76 | 48,299.03 | |
FCF | 143,337.07 | 88,863.40 | 127,727.20 | 176,822.93 | 241,537.84 | |
PV | 143,337.07 | 82,494.80 | 110,075.51 | 141,465.18 | 179,390.65 | |
TV | 11,055,470.33 | |||||
PTV | 7,622,466.07 | |||||
EV (Enterprise Value) | 8,279,229.27 |
Conclusion
Boston Scientific acquired Penumbra for $14.5B, which represents a ~1.75x premium over the calculated EV of $8.28B. This premium likely reflects multiple aspects for which I do not have direct visibility, such as synergies that could reduce costs, cross-selling opportunities, and Penumbra’s product development pipeline with potential future innovations. Additionally, the premium may also reflect strategic urgency, competitive pressures, and the rapid adoption of mechanical thrombectomy as standard care.
As such, Boston Scientific appears to have paid a reasonable price for Penumbra at a time when market growth, adoption trends, and the company’s financial health make this acquisition strategically sensible.
Sources:
Comments